{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:15:22Z","timestamp":1778217322594,"version":"3.51.4"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00117","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T01:04:15Z","timestamp":1581383055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine"],"prefix":"10.3389","volume":"10","author":[{"given":"Sneha R.","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Somarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"Altunel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Selmic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Byrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya U.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serene","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Devos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Soderblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. David","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Eward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J Health Econ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"B3","unstructured":"HowladerN\n            NooneAM\n            KrapchoM\n            MillerD\n            BrestA\n            YuM\n          Bethesda, MDNational Cancer InstituteSEER Cancer Statistics Review, 1975-20162019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41388-017-0018-x","article-title":"Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases","volume":"37","author":"Blomme","year":"2018","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nature10937","article-title":"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response","volume":"483","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejca.2003.10.011","article-title":"Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas","volume":"40","author":"Fichtner","year":"2004","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","article-title":"A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer","volume":"10","author":"Hidalgo","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.28696","article-title":"Patient-derived xenografts for individualized care in advanced sarcoma","volume":"120","author":"Stebbing","year":"2014","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5326\/0410241","article-title":"Soft-tissue sarcomas in dogs: a review","volume":"41","author":"Ehrhart","year":"2005","journal-title":"J Am Anim Hosp Assoc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejca.2012.09.011","article-title":"Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project","volume":"49","author":"Stiller","year":"2013","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1748-5827.2002.tb00066.x","article-title":"Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs","volume":"43","author":"Dobson","year":"2002","journal-title":"J Small Anim Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcpa.2014.09.005","article-title":"Comparative pathology of canine soft tissue sarcomas: possible models of human non-rhabdomyosarcoma soft tissue sarcomas","volume":"152","author":"Milovancev","year":"2015","journal-title":"J Comp Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e38422","DOI":"10.1371\/journal.pone.0038422","article-title":"Histological and molecular evaluation of patient-derived colorectal cancer explants","volume":"7","author":"Uronis","year":"2012","journal-title":"PLoS ONE."},{"key":"B17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11626-007-9060-2","article-title":"Species identification in cell culture: a two-pronged molecular approach","volume":"43","author":"Cooper","year":"2007","journal-title":"In vitro Cell Dev Biol Anim"},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ijc.25024","article-title":"Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma","volume":"127","author":"Long","year":"2010","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/15384047.2015.1040964","article-title":"The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma","volume":"16","author":"Hu","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B20","unstructured":"BioinformaticsB\n          Trim Galore2018"},{"key":"B21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"11 10 11","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinform."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with burrows-wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"B24","unstructured":"BroadInstitute\n          Picard toolkit."},{"key":"B25","doi-asserted-by":"publisher","first-page":"D91","DOI":"10.1093\/nar\/gkr895","article-title":"Ensembl genomes: an integrative resource for genome-scale data from non-vertebrate species","volume":"40","author":"Kersey","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1098\/rstb.2005.1669","article-title":"Using the quantitative genetic threshold model for inferences between and within species","volume":"360","author":"Felsenstein","year":"2005","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/bioinformatics\/bty633","article-title":"Ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R","volume":"35","author":"Paradis","year":"2018","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1093\/bioinformatics\/btr330","article-title":"The variant call format and VCFtools","volume":"27","author":"Danecek","year":"2011","journal-title":"Bioinformatics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"D754","DOI":"10.1093\/nar\/gkx1098","article-title":"Ensembl 2018","volume":"46","author":"Zerbino","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/1471-2164-9-488","article-title":"BioVenn - a web application for the comparison and visualization of biological lists using area-proportional venn diagrams","volume":"9","author":"Hulsen","year":"2008","journal-title":"BMC Genomics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","article-title":"UpSetR: an R package for the visualization of intersecting sets and their properties","volume":"33","author":"Conway","year":"2017","journal-title":"Bioinformatics"},{"key":"B32","volume-title":"A Cross-Species Personalized Medicine Pipeline Identifies the CRM1 Export Pathway as a Potentially Novel Treatment for Osteosarcoma.","author":"Lazarides","year":"2019"},{"key":"B33","doi-asserted-by":"publisher","first-page":"16820","DOI":"10.1038\/s41598-018-34887-6","article-title":"Blocking nuclear export of HSPA8 after heat shock stress severely alters cell survival","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nchembio.2386","article-title":"Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase","volume":"13","author":"Scott","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e61367","DOI":"10.1371\/journal.pone.0061367","article-title":"Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs","volume":"8","author":"Araujo","year":"2013","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1038\/emm.2017.165","article-title":"The significance of intertumor and intratumor heterogeneity in liver cancer","volume":"50","author":"Liu","year":"2018","journal-title":"Exp Mol Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer heterogeneity: implications for targeted therapeutics","volume":"108","author":"Fisher","year":"2013","journal-title":"Br J Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","article-title":"Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma","volume":"120","author":"Walker","year":"2012","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bbrc.2015.01.064","article-title":"Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis","volume":"458","author":"Kogita","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10825","article-title":"Clonal selection drives genetic divergence of metastatic medulloblastoma","volume":"482","author":"Wu","year":"2012","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/nm.3915","article-title":"Toward understanding and exploiting tumor heterogeneity","volume":"21","author":"Alizadeh","year":"2015","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2174\/1568009615666150629132157","article-title":"The anthelmintic drug niclosamide inhibits the proliferative activity of human osteosarcoma cells by targeting multiple signal pathways","volume":"15","author":"Liao","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"B50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1158\/1078-0432.CCR-15-0620","article-title":"Afatinib plus cetuximab delays resistance compared to single-agent erlotinib or afatinib in mouse models of TKI-naive EGFR L858R-induced lung adenocarcinoma","volume":"22","author":"Pirazzoli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"Janjigian","year":"2014","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/2159-8290.CD-15-0063","article-title":"Combined EGFR\/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer","volume":"5","author":"Tricker","year":"2015","journal-title":"Cancer Discov"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"B54","first-page":"6174","article-title":"Blockade of Hsp27 overcomes bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1600-0463.2011.02836.x","article-title":"Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt\/mTOR activity","volume":"120","author":"Que","year":"2012","journal-title":"APMIS"},{"key":"B57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1440-1827.1985.tb02211.x","article-title":"Smooth and skeletal muscle myosins in spindle cell tumors of soft tissue. an immunohistochemical study","volume":"35","author":"Saku","year":"1985","journal-title":"Acta Pathol Jpn"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T01:04:20Z","timestamp":1581383060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":57,"alternative-id":["10.3389\/fonc.2020.00117"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00117","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/517086","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"article-number":"117"}}